2015
DOI: 10.1016/j.brs.2015.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Influence of Zonisamide on the LTP-like Effect Induced by Quadripulse Transcranial Magnetic Stimulation (QPS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 12 publications
(5 citation statements)
references
References 19 publications
0
5
0
Order By: Relevance
“…18 These findings of dopamine agonist effects are consistent with the results from animal studies. Zonisamide mildly enhances LTP-like effects in M1, 23 possibly through induction of dopamine release 24,25 or MAO-B inhibition. 26 This LTP enhancement may partly explain the anti-Parkinsonian effects of zonisamide.…”
Section: Dopamine and Synap Tic Pl A S Ti Cit Y In Animal S And He Al...mentioning
confidence: 99%
“…18 These findings of dopamine agonist effects are consistent with the results from animal studies. Zonisamide mildly enhances LTP-like effects in M1, 23 possibly through induction of dopamine release 24,25 or MAO-B inhibition. 26 This LTP enhancement may partly explain the anti-Parkinsonian effects of zonisamide.…”
Section: Dopamine and Synap Tic Pl A S Ti Cit Y In Animal S And He Al...mentioning
confidence: 99%
“…82 Finally, 1 study in 24 participants has examined the influence of zonisamide (25 mg), a T-type VGCC antagonist, using QPS5. 90 In a crossover design, participants received either zonisamide or placebo before QPS5. The MEP amplitude trended higher with zonisamide on board, though this effect was not statistically significant.…”
Section: Ion Channels (5 Studies)mentioning
confidence: 99%
“…An important caveat to the literature to date is the predominance of small sample sizes and crossover designs, with only 4 studies using samples of 20 or more participants per group or crossover arm. 11,54,62,90 As such, while there appears to be broad alignment between the ex vivo tractable species literature and the human TMS literature, more adequately powered studies are required to determine if pharmacological adjuncts to rTMS plasticity protocols deviate from the preclinical literature.…”
Section: Limitationsmentioning
confidence: 99%
“…The lack of neural plasticity was normalized by taking L-Dopa in parallel with the improvement of motor symptoms (Enomoto et al 2012). Zonisamide, one of the anti-parkinsonian drugs, normalized the LTP-like effects by QPS5 in non-responder patients with Parkinson's disease (Tanaka et al 2015).…”
Section: Parkinson's Diseasementioning
confidence: 99%